An observational study in Chronic Migraine, Episodic Migraine and Migraine, sponsored by AbbVie. Recruiting at 36 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by AbbVie · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Migraine Disorders by AbbVie — 9 open to participants now, 13 under way, 7 of them phase 3. Migraine Disorders · AbbVie.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 2nd largest by planned enrollment of the 14 observational ones that give a count, is one of 5 that started in 2024, is one of 14 observational ones, reaches primary completion later than 9 of the 12 other live ones, and was the 50th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →9 of the 55 studies in Migraine Disorders by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18+
AbbVie · Sites in United States, Canada, Denmark and 8 more countries
Ages 12–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
AbbVie · Sites in United States, Canada
Ages 18+ · Women only
AbbVie · Sites in United States, Puerto Rico
Ages 6–17
By country, each count listing its studies:
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 31 · Phase 4 5
First in 2006; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 138 across 332 observational studies indexed under Migraine Disorders.
Median enrollment 524 across the 41 interventional studies, 431 across the 14 observational. Of the 40 that completed or were terminated, 32 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
4 of the studies in Migraine Disorders by AbbVie that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05125302Phase 3AbbVieStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | 2027-05 |
| NCT06417775Phase 3AbbVieStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | 2027-11 |
| NCT06602479AbbVieA Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine | 2027-02 |
| NCT07310290AbbVieStudy to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks | 2027-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Migraine Disorders by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice.
Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea.
Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Adult participants who have been prescribed atogepant for preventive treatment migraine according to the latest approved local label in routine clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive atogepant as prescribed by their physician according to the local label.
Drug: Atogepant
Oral Tablet
Also known as: Qulipta, Aquipta
Percentage (%) of participants who reported serious adverse event (SAE)/drug reaction (SADR)
Percentage (%) of participants who reported serious adverse event (SAE)/drug reaction (SADR)
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants who reported unexpected (not reflected in the latest approved label) adverse event (AE)/drug reaction (ADR)
Percentage (%) of participants who reported unexpected (not reflected in the latest approved label) adverse event (AE)/drug reaction (ADR)
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants who reported known (labeled) ADR
Percentage (%) of participants who reported known (labeled) ADR
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants who reported non-serious AE/ADR
Percentage (%) of participants who reported non-serious AE/ADR
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants who reported the events related to important potential risks and missing information defined in the Risk Management Plan (RMP)
Percentage (%) of participants who reported the events related to important potential risks and missing information defined in the RMP
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants with AE: overall summary
Percentage (%) of participants with AE: overall summary
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants with common (>=5%) AE
Percentage (%) of participants with common (\>=5%) AE
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants with AE leading to treatment discontinuation
Percentage (%) of participants with AE leading to treatment discontinuation
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants who reported treatment-related AE per the investigator causality assessment
Percentage (%) of participants who reported treatment-related AE per the investigator causality assessment
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants who reported treatment-related serious AE per the investigator causality assessment
Percentage (%) of participants who reported treatment-related serious AE per the investigator causality assessment
Time frame: Up to approximately 16 Weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for May 2029, 56 months after the start.
Of 160 observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 56 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.